{"entity":"eli-lilly","id":"ent_eli-lilly","name":"Eli Lilly and Company","from":"2025-11-08","to":"2026-11-08","page":"https://asof.is/record/eli-lilly/diff?from=2025-11-08&to=2026-11-08","summary":"Between 2025-11-08 and 2026-11-08, Eli Lilly and Company's record changed in 14 facts: 2 replaced (net income $10.59 billion → $20.64 billion; revenue $45.04 billion → $65.18 billion), 6 added, 6 ended; 10 unchanged.","counts":{"changed":14,"added":6,"ended":6,"replaced":2,"unchanged":10,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"cash_and_equivalents","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_net_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_revenue","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"shares_outstanding","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_assets","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_equity","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"quarterly_research_and_development","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"research_and_development","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[{"id":"clm_BC1171A7B218","predicate":"cash_and_equivalents","value":"4,885,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 4,885,000,000 United States dollar\", as of 2026-09-30. Claim clm_BC1171A7B218, https://asof.is/claim/clm_BC1171A7B218, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_BC1171A7B218","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-10-29"}},{"id":"clm_9D57FD94603E","predicate":"quarterly_net_income","value":"6,451,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 6,451,000,000 United States dollar\", as of 2026-09-30. Claim clm_9D57FD94603E, https://asof.is/claim/clm_9D57FD94603E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_9D57FD94603E","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-29"}},{"id":"clm_E1B01E0405B5","predicate":"quarterly_revenue","value":"24,397,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 24,397,000,000 United States dollar\", as of 2026-09-30. Claim clm_E1B01E0405B5, https://asof.is/claim/clm_E1B01E0405B5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_E1B01E0405B5","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2026, filed 2026-10-29"}},{"id":"clm_ACF69B8AA825","predicate":"shares_outstanding","value":"940,745,031 shares","valid_from":"2026-10-26","valid_to":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 940,745,031 shares\", as of 2026-10-26. Claim clm_ACF69B8AA825, https://asof.is/claim/clm_ACF69B8AA825, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_ACF69B8AA825","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-10-29"}},{"id":"clm_D20ADDDE60AB","predicate":"total_assets","value":"148,072,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 148,072,000,000 United States dollar\", as of 2026-09-30. Claim clm_D20ADDDE60AB, https://asof.is/claim/clm_D20ADDDE60AB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_D20ADDDE60AB","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-10-29"}},{"id":"clm_82ACC132512E","predicate":"total_equity","value":"40,271,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 40,271,000,000 United States dollar\", as of 2026-09-30. Claim clm_82ACC132512E, https://asof.is/claim/clm_82ACC132512E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm.","url":"https://asof.is/claim/clm_82ACC132512E","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/0000059478-26-000108-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-10-29"}}],"ended":[{"id":"clm_599C7D287C29","predicate":"cash_and_equivalents","value":"9,791,900,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company cash and equivalents: 9,791,900,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_599C7D287C29, https://asof.is/claim/clm_599C7D287C29, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_599C7D287C29","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AEB07A485FC9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_74B5C29B477B","predicate":"quarterly_net_income","value":"5,582,500,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly net income: 5,582,500,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_74B5C29B477B, https://asof.is/claim/clm_74B5C29B477B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_74B5C29B477B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_063460475B4C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_D3881089FBD6","predicate":"quarterly_revenue","value":"17,600,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company quarterly revenue: 17,600,800,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_D3881089FBD6, https://asof.is/claim/clm_D3881089FBD6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_D3881089FBD6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DF742A5515B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_3242C5557E98","predicate":"shares_outstanding","value":"945,383,757 shares","valid_from":"2025-10-27","valid_to":"2026-02-09","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company shares outstanding: 945,383,757 shares\", as of 2025-10-27 (until 2026-02-09). Claim clm_3242C5557E98, https://asof.is/claim/clm_3242C5557E98, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_3242C5557E98","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5A4FA78D8054","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_C3E87E59336F","predicate":"total_assets","value":"114,935,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total assets: 114,935,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_C3E87E59336F, https://asof.is/claim/clm_C3E87E59336F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_C3E87E59336F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C278ED944402","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-30"}},{"id":"clm_AA3E6D040F0E","predicate":"total_equity","value":"23,793,300,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company total equity: 23,793,300,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_AA3E6D040F0E, https://asof.is/claim/clm_AA3E6D040F0E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm.","url":"https://asof.is/claim/clm_AA3E6D040F0E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6628DA8282A8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000254/0000059478-25-000254-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-30"}}],"replaced":[{"predicate":"net_income","from":{"id":"clm_2BC21A73296C","predicate":"net_income","value":"10,590,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 10,590,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_2BC21A73296C, https://asof.is/claim/clm_2BC21A73296C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_2BC21A73296C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DBEC55E24C06","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-19T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-19"}},"to":{"id":"clm_DBEC55E24C06","predicate":"net_income","value":"20,640,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company net income: 20,640,000,000 United States dollar\", as of 2025-12-31. Claim clm_DBEC55E24C06, https://asof.is/claim/clm_DBEC55E24C06, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm.","url":"https://asof.is/claim/clm_DBEC55E24C06","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-12"}}},{"predicate":"revenue","from":{"id":"clm_282E1F71B318","predicate":"revenue","value":"45,042,700,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-19","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 45,042,700,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_282E1F71B318, https://asof.is/claim/clm_282E1F71B318, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm.","url":"https://asof.is/claim/clm_282E1F71B318","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C4636B99C62B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/0000059478-25-000067-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-19T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-19"}},"to":{"id":"clm_C4636B99C62B","predicate":"revenue","value":"65,179,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Eli Lilly and Company revenue: 65,179,000,000 United States dollar\", as of 2025-12-31. Claim clm_C4636B99C62B, https://asof.is/claim/clm_C4636B99C62B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm.","url":"https://asof.is/claim/clm_C4636B99C62B","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/0000059478-26-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2025, filed 2026-02-12"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}